Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Luminespib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.